Latest Tax Incentives News

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Parkway Corporate Limited reports a robust December quarter with a 420% revenue increase and key milestones in brine processing technology, positioning itself as a pivotal player in Queensland's CSG industry.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Mighty Kingdom Ltd has appointed Dylan Miklashek as Interim CEO and Duncan Gordon as Non-Executive Chair, signaling a fresh leadership approach amid a company restructuring.

Hazer Group has successfully completed its Commercial Demonstration Plant program ahead of schedule, validating its methane pyrolysis technology and securing significant funding to accelerate commercialisation in 2025.

Andromeda Metals has secured a $2.34 million R&D tax refund for the 2024 financial year, reinforcing its funding strategy and underpinning development of the Great White Project.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

HITIQ Limited has received $1.6 million from the R&D Tax Incentive Scheme, using most of it to repay its RDTI Facility with Keystone Capital Partners, signaling a strategic move to streamline its R&D funding.

FBR Limited has received a substantial A$6.3 million R&D tax incentive rebate from the Australian Taxation Office, strengthening its financial position as it wraps up its US Demonstration Program with additional funding from CRH Ventures.

Livium and Mineral Resources have agreed to extend their joint development agreement, funding additional optimisation activities for the LieNA® lithium extraction technology and setting the stage for a 50/50 joint venture.